Division of Microbiology, Calgary Laboratory Services, University of Calgary, Calgary, Alberta, Canada.
Int J Antimicrob Agents. 2010 Apr;35(4):316-21. doi: 10.1016/j.ijantimicag.2009.11.003. Epub 2010 Jan 13.
Since 2000, Escherichia coli producing CTX-M enzymes have emerged worldwide as important causes of community-onset urinary tract and bloodstream infections owing to extended-spectrum beta-lactamase (ESBL)-producing bacteria. Molecular epidemiological studies suggested that the sudden worldwide increase of CTX-M-15-producing E. coli was mainly due to a single clone (ST131) and that foreign travel to high-risk areas, such as the Indian subcontinent, might in part play a role in the spread of this clone across different continents. Empirical antibiotic coverage for these resistant organisms should be considered in community patients presenting with sepsis involving the urinary tract, especially if the patient recently travelled to a high-risk area. If this emerging public health threat is ignored, it is possible that the medical community may be forced, in the near future, to use carbapenems as the first choice for the empirical treatment of serious infections associated with urinary tract infections originating from the community.
自 2000 年以来,产 CTX-M 酶的大肠杆菌由于产超广谱β-内酰胺酶(ESBL)的细菌,已成为社区获得性尿路感染和血流感染的重要原因。分子流行病学研究表明,CTX-M-15 产大肠杆菌的全球突然增加主要归因于单一克隆(ST131),前往高危地区(如印度次大陆)的旅行在一定程度上可能导致该克隆在不同大陆之间传播。对于社区中出现尿路感染合并脓毒症的患者,应考虑针对这些耐药菌的经验性抗生素治疗。如果忽略这种新出现的公共卫生威胁,在不久的将来,医学界可能被迫将碳青霉烯类药物作为经验性治疗与社区获得性尿路感染相关的严重感染的首选药物。